Can-Fite BioPharma has filed a patent for an A3 adenosine receptor (A3AR) ligand that can be used to treat advanced solid tumors, specifically hepatocellular carcinoma (HCC) in mammals. The patent claims a method of treatment by administering the A3AR ligand or a pharmaceutical composition containing it to a mammalian subject with an advanced solid tumor. GlobalData’s report on Can-Fite BioPharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Can-Fite BioPharma, cancer treatment biomarkers was a key innovation area identified from patents.
Treatment of advanced solid tumors using an a3ar ligand
A recently filed patent (Publication Number: US20230201240A1) describes a method for treating advanced solid tumors, specifically advanced hepatocellular carcinoma (HCC). The method involves administering an A3 adenosine receptor (A3AR) ligand or a pharmaceutical composition containing the ligand to a mammalian subject in need of treatment. The A3AR ligand can be an agonist or an allosteric modulator of the A3AR.
The patent claims also mention the use of additional therapeutic agents, such as anti-cancer drugs like monoclonal antibodies and multi-kinase inhibitors, in combination with the A3AR ligand. This combination therapy aims to enhance the treatment efficacy.
The method is particularly applicable to subjects with advanced HCC and a Child-Pugh B (CPB) cirrhosis score of 7, 8, or 9. The A3AR ligand can be administered once daily, twice daily, or thrice daily, with a recommended dosage range of 50 µg/kg to 10 mg/kg body weight. In the case of Cl-IB-MECA, a specific A3AR ligand, an oral dose of 1-50 mg, preferably 5-30 mg twice daily, is suggested.
The patent also claims that the administration of the A3AR ligand, specifically Cl-IB-MECA, can increase the overall survival of subjects with advanced HCC and a CPB7 score. The increase in overall survival can be measured after a treatment period of 9 months, 10 months, 12 months, or more. The method can be used as a second-line therapy and can be administered for a treatment period of at least 9 months, up to 5 years or more.
Furthermore, the patent describes a pharmaceutical composition comprising the A3AR ligand, such as Cl-IB-MECA, along with a pharmaceutically acceptable carrier or diluent. This composition is intended to increase the overall survival of subjects with advanced HCC and a CPB7 score, with a recommended treatment period of 12 months or more.
In summary, the patent presents a method and pharmaceutical composition for treating advanced solid tumors, specifically advanced hepatocellular carcinoma. The use of an A3 adenosine receptor ligand, such as Cl-IB-MECA, either alone or in combination with other therapeutic agents, aims to improve overall survival in subjects with advanced HCC and a CPB7 score. The method allows for flexible dosing regimens and can be administered for extended treatment periods.
To know more about GlobalData’s detailed insights on Can-Fite BioPharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
